<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US" xmlns:georss="http://www.georss.org/georss">
  <title type="text">ReleaseWire - Latest Press Releases - Healthcare &gt; Pharmaceuticals</title>
  <link href="http://feeds.releasewire.com/atom/full/industry/177" rel="self" type="application/atom+xml"/>
  <link href="http://www.releasewire.com/press-releases/healthcare/pharmaceuticals/" rel="alternate" type="text/html"/>
  <link href="http://sbwire.superfeedr.com/" rel="hub"/>
  <logo>http://media.releasewire.com/photos/show/?id=68004&amp;size=small</logo>
  <updated>2026-05-01T17:40:40-05:00</updated>
  <author>
    <name>ReleaseWire</name>
    <email>support@releasewire.com</email>
  </author>
  <id>http://www.releasewire.com//atom/full/industry/177</id>
  <entry>
    <title type="text">Ace Therapeutics Accelerates Preclinical Psychiatry Research by Rolling out Customized Animal Models</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2025-04-04T08:45:00-05:00</published>
    <updated>2025-04-04T08:45:00-05:00</updated>
    <author>
      <name>Ace Therapeutics</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 04/04/2025 -- As a preclinical contract research provider dedicated to offering comprehensive research services, Ace Therapeutics provides a complete one-stop service for developing custom animal models to support &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.acetherapeutics.com/psychiatry/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.acetherapeutics.com/psychiatry/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;preclinical psychiatry research&amp;lt;/a&amp;gt;. The opportunity to apply such models towards revolutionizing research in mental health can allow for the discovery of novel therapies for these disorders.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Psychiatry research faces a number of hurdles to the translation of?preclinical discoveries into effective treatments,&amp;quot; said the senior chief scientist at Ace Therapeutics. &amp;quot;We pride?ourselves on being able to create customized animal models, enabling researchers to make more sense of the complexities surrounding mental health disorders and developing efficient therapeutic adjuncts.&amp;quot; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Current challenges in preclinical psychiatry research&amp;lt;br /&amp;gt;
At this stage, preclinical research on mental diseases has many challenges and difficulties, such as animal models are limited, pathological mechanisms are complex, drug targets are unclear, and behavioral testing methods are?not advanced enough. To this end, preclinical studies on psychiatric disorders may have to create?more productive animal and in vitro models and enhance biomarker discovery and validation to accelerate the discovery of novel therapeutic strategies for psychiatric diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Through approaches such as selective breeding, genetic engineering, brain injury, and environmental manipulation, Ace Therapeutics has developed a range of?&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.acetherapeutics.com/psychiatry/animal-models-in-psychiatry.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.acetherapeutics.com/psychiatry/animal-models-in-psychiatry.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;animal models for psychiatric research&amp;lt;/a&amp;gt;. These models represent attempts to simulate, as?much as possible, the neurobiological or behavioral pathology of human diseases. Therefore, it can help researchers elucidate disease pathophysiology and also expedite therapeutic development?targeting novel molecular targets.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Some of the main features of?Ace Therapeutics&amp;#039; animal models include:&amp;lt;br /&amp;gt;
&amp;ndash; Genetically-Engineered?Models: Models that can be genetically engineered to manifest specific traits related to different psychiatric conditions such as depression, anxiety, and autism, enabling targeted research.&amp;lt;br /&amp;gt;
- Robust Validation: Extensive?validation studies are performed with experienced psychiatric researchers to confirm that the models accurately represent human pathophysiology.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
In this context, the launch of Ace Therapeutics&amp;#039; preclinical psychiatry models comes in response to increasing demand for better preclinical?research tools. Utilizing leading-edge genetic modification and behavioral evaluation techniques, Ace Therapeutics offers researchers the?ability to model a multitude of psychiatric disorders with unparalleled precision. The company is confident that these models can facilitate groundbreaking discoveries and accelerate the pathway from bench to bedside.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Therapeutics&amp;lt;br /&amp;gt;
With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative mental illness therapies. From basic research services to therapeutic development services, Ace Therapeutics offers tailored solutions to facilitate psychiatric drug development, enabling the transformation of promising concepts into promising therapeutic candidates.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1385702&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.acetherapeutics.com/&amp;quot;&amp;gt;https://www.acetherapeutics.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1385702&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Ace Therapeutics Releases Proteomic Analysis Services for Glaucoma Research</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2024-05-30T08:15:00-05:00</published>
    <updated>2024-05-30T08:15:00-05:00</updated>
    <author>
      <name>Ace Therapeutics</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 05/30/2024 -- Ace Therapeutics, an integrated service provider for glaucoma research, is proud to announce the release of its &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.acetherapeutics.com/glaucoma/proteomic-analysis-of-glaucoma.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.acetherapeutics.com/glaucoma/proteomic-analysis-of-glaucoma.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;proteomic analysis services for glaucoma research&amp;lt;/a&amp;gt;. These cutting-edge analysis services are expected to revolutionize the way researchers approach the study of glaucoma, a leading cause of irreversible blindness worldwide.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Glaucoma is a group of eye diseases characterized by damage to the optic nerve, usually due to high intraocular pressure (IOP). If not diagnosed and treated early, glaucoma can lead to loss of vision. There are several types of glaucoma, including open-angle, closed-angle, normal-tension, and congenital. Proteomics is the study of proteins and their functions within a biological system. Proteomics studies can help researchers uncover glaucoma-related changes in different tissues and biological fluids of the eye. By utilizing state-of-the-art technologies and techniques, Ace Therapeutics&amp;#039;s proteomic analysis services will allow researchers to better understand the molecular mechanisms underlying glaucoma and develop innovative treatment strategies.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Glaucoma is a complex disease with a significant impact on millions of people around the world. Our proteomic analysis services can provide researchers with invaluable insights into the biological pathways involved in glaucoma and pave the way for new therapeutic interventions.&amp;quot; said the chief scientific officer at Ace Therapeutics.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Realizing the aqueous humor (AH) is a key site for studying the pathogenesis of glaucoma, Ace Therapeutics&amp;#039;s team of experts can conduct quantitative &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.acetherapeutics.com/glaucoma/proteomic-analysis-of-aqueous-humor-in-glaucoma.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.acetherapeutics.com/glaucoma/proteomic-analysis-of-aqueous-humor-in-glaucoma.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;glaucoma AH proteomic analysis&amp;lt;/a&amp;gt; to detect changes in protein expression, offering valuable information for biomarker discovery and enhancing the knowledge of the molecular mechanisms of glaucoma. Additionally, the company can also provide proteomic analysis of vitreous humor (VH) services to assist researchers in discussing and expanding their findings on glaucoma.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
At Ace Therapeutics, its expert team will take care of the sample preparation of different ocular tissues and biological fluids associated with glaucoma, complex analytical experiments as well as data analysis using mass spectrometry, bioinformatics, and many other advanced technologies and facilities. These services are tailored to meet the specific needs of researchers working in both academic and industry settings.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Therapeutics&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.acetherapeutics.com/glaucoma/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.acetherapeutics.com/glaucoma/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Ace Therapeutics Glaucoma&amp;lt;/a&amp;gt; is an innovative glaucoma disease research company that offers a wide range of services in basic research, drug development, and preclinical studies, delivering innovative and high-quality solutions to worldwide clients. Ace Therapeutics is committed to being a leader in the field of glaucoma research, providing unique drug development and preclinical research solutions to advance clients&amp;#039; project development.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1384069&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.acetherapeutics.com/glaucoma/&amp;quot;&amp;gt;https://www.acetherapeutics.com/glaucoma/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1384069&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Ace Infectious Announces Antimicrobial Peptide Development Services to Drive Forward Drug Development Against Superbugs</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2024-04-15T13:35:00-05:00</published>
    <updated>2024-04-15T13:35:00-05:00</updated>
    <author>
      <name>Ace Infectious</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 04/15/2024 -- Ace Infectious, a one-stop shop for researchers devoted to making advancements in infectious diseases including superbugs and H. pylori, is thrilled to announce the launch of its &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.superbioz.com/antimicrobial-peptides-development.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.superbioz.com/antimicrobial-peptides-development.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;antimicrobial peptide development services&amp;lt;/a&amp;gt;. This ground-breaking service will revolutionize drug development efforts against the growing threat of superbugs, providing innovative solutions to combat infectious diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Antimicrobial peptides (AMPs) are small molecules that have shown promise in the fight against drug-resistant bacteria, fungi, and viruses. More than two thousand AMPs have been identified and isolated from a wide range of organisms, including plants, insects, amphibians, humans, and even bacteria. Ace Infectious&amp;#039; antimicrobial peptide development services can help researchers find natural AMPs, explore their mechanisms of antimicrobial activity, optimize antimicrobial activity, and minimize toxicity and production costs. By harnessing the power of AMPs, Ace Infectious aims to develop novel antimicrobial therapies that can effectively target and eliminate even the most stubborn pathogens.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The antimicrobial peptide development solutions offered by &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.superbioz.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.superbioz.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Ace Infectious&amp;lt;/a&amp;gt; encompass a range of services, including the isolation and characterization of AMPs from microbial sources, plants, and animals, peptide design and modification, as well as AMP delivery systems. These services are tailored to meet the unique needs of each client, providing a customized approach to drug development that leverages cutting-edge technology and expertise.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Our antimicrobial peptide development services represent a significant step forward in the battle against superbugs,&amp;quot; said the marketing manager at Ace Infectious. &amp;quot;With the rise of antibiotic resistance poses a serious threat to public health, we closely partner with pharmaceutical companies, biotech firms, and research institutions to advance the development of novel antimicrobial therapies. &amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
In addition to AMP development services, Ace Infectious also provides services to support &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.hpylorimed.com/h-pylori-drug-development-services.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.hpylorimed.com/h-pylori-drug-development-services.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;H. pylori drug development&amp;lt;/a&amp;gt;, including target discovery and validation, targeted drug development, and H. pylori drug analysis. These services further solidify its position in the research of infectious diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Infectious&amp;lt;br /&amp;gt;
Ace Infectious is a comprehensive biotechnology company that provides a wide range of professional services and products in the field of drug-resistant bacteria research, covering basic research, various types of anti-superbug drug development, as well as innovative H. pylori research services. Backed by extensive research and rich expertise, the company closely works with world-class scientists, virologists, and infectious disease experts to revolutionize the treatment landscape for antibiotic-resistant infections through its innovative therapy development solutions.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1383814&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.superbioz.com/&amp;quot;&amp;gt;https://www.superbioz.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1383814&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Amerigo Scientific's GC Capillary Columns Enable Exceptional Analytical Performance</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2024-04-15T08:15:00-05:00</published>
    <updated>2024-04-15T08:15:00-05:00</updated>
    <author>
      <name>Amerigo Scientific</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 04/15/2024 -- Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, is pleased to announce the launch of its new line of gas chromatography (GC) capillary columns. These columns offer unparalleled performance and reliability, making them an essential tool for laboratories looking to achieve precise and accurate analytical results.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Our GC capillary columns are engineered to meet the highest standards of quality and performance,&amp;quot; said the business development manager of Amerigo Scientific. &amp;quot;We are confident that these columns will help researchers achieve superior analytical results and drive innovation in their research and development efforts.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/gas-chromatography-columns.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/gas-chromatography-columns.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Gas chromatography columns&amp;lt;/a&amp;gt; are devices that utilize chromatographic technologies to separate volatile compounds swiftly and effectively, such as packed and capillary columns. In contrast to traditional packed columns, capillary columns are known for their exceptional separation performance due to their low diffusion rates and excellent permeability, which makes them ideal for highly sensitive analytical detection. GC capillary columns are used for detecting impurities in petroleum and industry and determining sample composition in pharmaceutical and clinical experiments.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Amerigo Scientific offers a range of GC capillary columns with various lengths, internal diameters, and coatings to suit different GC instrumentation and analytical requirements. These columns are made up of a thin tube of fused silica glass or stainless steel, with chemically bonded layers or coatings of stationary phase on the inner surface. The inert and flexible nature of the fused silica materials allows for top-notch separations and easy handling. Additionally, the type of stationary phase used directly impacts the efficiency and polarity of the column, with a range of ten stationary phase options available, spanning from non-polar to highly polar.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Amerigo Scientific&amp;#039;s &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/gc-capillary-columns.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/gc-capillary-columns.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;GC capillary columns&amp;lt;/a&amp;gt; adhere to standard chromatographic parameters and column performance, ensuring quality in key properties such as column efficiency, polarity, surface inertness, and thermal stability. In addition to their exceptional analytical performance, these GC capillary columns are also compatible with a wide range of GC instruments, making them a versatile and cost-effective solution for laboratories of all sizes.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Amerigo Scientific&amp;lt;br /&amp;gt;
Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation to all companies and institutions in the branch of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers&amp;#039; questions or concerns and are always ready to provide individualized customer service of high standards.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Phoebe Davis&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1383754&amp;quot;&amp;gt;Click to Email Phoebe Davis&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.amerigoscientific.com/&amp;quot;&amp;gt;https://www.amerigoscientific.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1383754&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Rdcthera Announces RDC Development and Analysis Services Based on Its Technology Platform</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2024-01-17T11:46:00-06:00</published>
    <updated>2024-01-17T11:46:00-06:00</updated>
    <author>
      <name>Rdcthera</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 01/17/2024 -- In a groundbreaking development for the field of drug discovery and diagnosis, Rdcthera, a professional CRO company offering efficient and customized R&amp;amp;D services related to radionuclide drug conjugates (RDCs), has announced the release of its RDC development and analysis services. Leveraging its cutting-edge technology platform, Rdcthera aims to empower drug developers with state-of-the-art tools for creating targeted radiopharmaceutical treatments.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;With our cutting-edge technology platform, Rdcthera is at the forefront of advancing the potential of radionuclide therapy,&amp;quot; said the marketing director at Rdcthera. &amp;quot;Our RDC development and analysis services will provide a comprehensive solution for pharmaceutical and biotech companies seeking a reliable partner to accelerate their development timelines and bring targeted cancer therapies to patients in need.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
RDCs represent a promising class of therapeutic agents that combine the selectivity of antibodies with the cell-killing properties of radioisotopes. By delivering precise cellular-level treatment to disease sites, RDCs show immense potential in treating various types of cancers and other medical conditions. The efforts to create RDC in Rdcthera benefit from the advanced RDC development and analysis platforms that are dedicated to providing worldwide customers with high-quality products, customized services, analytical testing services, and expert consulting for RDC development projects.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Rdcthera has been researching and optimizing the &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.rdcthera.com/rdc-development-service.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.rdcthera.com/rdc-development-service.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;radionuclide drug conjugate development&amp;lt;/a&amp;gt; for many years. To enable a robust and safe synthesis process of RDC, its chemical development group is fitted with fume hoods in multiple suites and also equipped with new-age technologies such as chemical synthesis and conjugation technology, software-based toxicity evaluation, quantitative risk assessment, and green chemistry to support its synthesis services for chemical molecules and chelators, as well as conjugation services.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
After the RDC synthesis process, the &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.rdcthera.com/rdc-analysis-service.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.rdcthera.com/rdc-analysis-service.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;analysis for RDC&amp;lt;/a&amp;gt;, both in vitro and in vivo, is required for quality control and characterization before further clinical studies. Through RDC binding analysis, biodistribution analysis, toxicity study, and many other advanced techniques, Rdcthera aids drug developers in assessing the radiation dose delivered by RDCs to healthy tissues surrounding the target site, which enables careful evaluation of potential side effects.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Combined with Rdcthera&amp;#039;s significant RDC expertise and proven platform technology, the company has the confidence to turn clients&amp;#039; materials into an RDC, enable scaling, and shorten the path to the clinic.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Rdcthera&amp;lt;br /&amp;gt;
Rdcthera, supported by its rich library of radionuclides, chelators, and linkers, is professional in radionuclide drug conjugate design, conjugation, and analysis. To expedite RDC development, Rdcthera has also established a professional RDC development platform to support high-quality RDC-related services.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1382020&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.rdcthera.com/&amp;quot;&amp;gt;https://www.rdcthera.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1382020&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">To Fight Superbugs, Ace Infectious Unveils Phage Therapy Development Services</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-12-27T11:01:00-06:00</published>
    <updated>2023-12-27T11:01:00-06:00</updated>
    <author>
      <name>Ace Infectious</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 12/27/2023 -- Ace Infectious announced today the launch of its phage therapy development services initiated with the aim of combating the global threat of superbugs. As a biotechnology company specializing in anti-superbug drug and therapy development, Ace Infectious is dedicated to providing innovative, effective, and safe development services to support scientific communities addressing the urgent need for alternative therapies to fight drug-resistant bacterial infections.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Superbugs, also known as antibiotic-resistant bacteria, are strains of bacteria that have developed the ability to resist the effects of traditional antibiotics. Traditional antibiotics have become increasingly ineffective in treating these infections, resulting in prolonged patient suffering and significant challenges for healthcare providers worldwide. Ace Infectious recognizes the urgent need for novel therapeutic options to address this growing crisis.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Phages are naturally occurring viruses that target and destroy bacteria, offering a promising solution that could revolutionize the way to combat infectious diseases. Ace Infectious brings together a team of experts to conduct &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.superbioz.com/phage-therapies-development-against-superbugs.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.superbioz.com/phage-therapies-development-against-superbugs.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;phage therapy development&amp;lt;/a&amp;gt; through phage discovery, isolation, characterization, cocktail design, engineering, and preclinical development programs for phage drug discovery. To maintain effectiveness against the emergence of drug-resistant bacterial pathogens, the company fully utilizes the diversity and specificity of phages to advance the development of sustainable and accessible superbug therapies.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;We are proud to unveil our phage therapy development in the fight against superbugs,&amp;quot; said the marketing manager of Ace Infectious. &amp;quot;At Ace Infectious, we believe that phage therapy holds enormous potential to revolutionize infectious disease treatments. Our team is dedicated to developing advanced therapies that not only overcome the limitations of traditional antibiotics but also support the global effort to combat antibiotic resistance.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
With unique development capabilities such as precisely targeted phage libraries, genomic screening, highly purified phage collection, and phage-bacteria matching technology, Ace Infectious aims to expedite the process of &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.superbioz.com/anti-superbug-drugs-development.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.superbioz.com/anti-superbug-drugs-development.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;anti-superbug drug development&amp;lt;/a&amp;gt; that can effectively target and eradicate drug-resistant bacterial infections. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Infectious&amp;lt;br /&amp;gt;
Ace Infectious is a comprehensive biotechnology company that provides a wide range of professional services and products in the field of drug-resistant bacteria research, covering basic research, various types of anti-superbug drug development, as well as innovative therapy development for common superbugs. Backed by extensive research and rich expertise, the company closely works with world-class scientists, virologists, and infectious disease experts to revolutionize the treatment landscape for antibiotic-resistant infections through its innovative therapy development solutions.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1381352&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.superbioz.com/&amp;quot;&amp;gt;https://www.superbioz.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1381352&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Ace Metabolism Advances Disease Research with Iron Metabolism Solutions</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-12-13T11:25:00-06:00</published>
    <updated>2023-12-13T11:25:00-06:00</updated>
    <author>
      <name>Ace Metabolism</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;Ace Metabolism unveils innovative iron metabolism-related disease research services to assist scientific researchers with relevant drug development and pathology studies.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 12/13/2023 -- Ace Metabolism, a leading biotechnology company, is making great strides in disease research through their innovative &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.metabolixis.com/iron-metabolism/iron-metabolism-related-disease-research-services.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.metabolixis.com/iron-metabolism/iron-metabolism-related-disease-research-services.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;iron metabolism-related disease research&amp;lt;/a&amp;gt; services. By unlocking the secrets of iron regulation within the body, Ace Metabolism is poised to transform the understanding and treatment of various iron metabolism-associated diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Iron metabolism-related diseases are one of the common diseases in humans, mainly manifested as iron deficiency or iron overload. For example, neurodegenerative diseases such as Huntington&amp;#039;s disease, Alzheimer&amp;#039;s disease, Parkinson&amp;#039;s disease, and Friedreich&amp;#039;s ataxia are reported to be associated with abnormal accumulation of iron in the brain. Iron deficiency anemia occurs when the balance of iron intake, iron stores, and body iron losses are not sufficient to fully support red blood cell production. There are also many other diseases caused by abnormal iron metabolism.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
To assist scientific researchers in drug development and pathological research, Ace Metabolism provides a range of research services related to iron metabolism-related diseases. Ace Metabolism&amp;#039;s cutting-edge research focuses on understanding the intricate mechanisms of iron metabolism and developing targeted solutions to combat related diseases. By delving deep into the molecular pathways involved in iron absorption, transport, and storage, the company aims to uncover new therapeutic interventions and diagnostic tools.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Ace Metabolism has been working on iron homeostasis-related diseases for many years and has a complete protein assay platform and equipment to provide diverse solutions for &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.metabolixis.com/iron-metabolism/iron-metabolism-related-neurodegenerative-disease-service.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.metabolixis.com/iron-metabolism/iron-metabolism-related-neurodegenerative-disease-service.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;iron metabolism-related neurodegenerative disease research&amp;lt;/a&amp;gt; according to the different needs of researchers. To help researchers explore how irregular iron status contributes to the development of neuronal diseases, Ace Metabolism can conduct MR quantification of brain iron deposition, brain ferritin gene assay, and iron metabolism detection in neurodegenerative diseases. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For iron-deficiency anemia research, Ace Metabolism establishes &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.metabolixis.com/iron-metabolism/iron-deficiency-anemia-research-service.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.metabolixis.com/iron-metabolism/iron-deficiency-anemia-research-service.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;iron-deficiency anemia animal models&amp;lt;/a&amp;gt; through low iron diets supplemented by regular bloodletting and regularly observes hemoglobin content, red blood cell count, hematocrit, and measure serum iron, serum ferritin, ferritin saturation, total iron binding capacity, etc. to help clients study the mechanism related to iron deficiency anemia. The company also provides iron metabolism assays and testing services to help researchers investigate the relationship and potential mechanisms of iron metabolism and iron deficiency anemia, laying the foundation for subsequent drug development and treatment.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Ace Metabolism has a professional team and advanced equipment, and the whole process is operated by experienced technicians to provide customers with iron metabolism-related disease research services. Moreover, the company can customize its technical solutions to meet the specific needs of customers to solve all the problems found in their research on different types of diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Metabolism&amp;lt;br /&amp;gt;
Ace Metabolism is a leading bespoke service provider with extensive experience in a wide range of cellular assays and metabolomics. Their services and products cover most of the studies related to the field of iron metabolism, aiming to help clients advance relevant drug development and pathology studies.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1380947&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.metabolixis.com/iron-metabolism/&amp;quot;&amp;gt;https://www.metabolixis.com/iron-metabolism/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1380947&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Amerigo Scientific's New Lab Offering: S-Silver SERS Substrates</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-12-06T10:50:00-06:00</published>
    <updated>2023-12-06T10:50:00-06:00</updated>
    <author>
      <name>Amerigo Scientific</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 12/06/2023 -- Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, announced the launch of its latest innovation in the field of surface-enhanced Raman spectroscopy (SERS) &amp;ndash; &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/s-silver-sers-substrates-item-110671.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/s-silver-sers-substrates-item-110671.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;S-Silver SERS substrates&amp;lt;/a&amp;gt;. With this exciting addition to its extensive product portfolio, Amerigo Scientific aims to empower researchers, scientists, and industry professionals with the most advanced tools for enhanced spectroscopic analysis.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The S-Silver SERS platform consists of an ITO glass that is coated with silver nanoparticles. These S-substrates are specifically designed for 96-well plates and provide exceptional enhancement (ranging from ppm to ppb, and even ppt) when compounds are deposited in a small volume of the analyzed solution. As a result, they are highly suitable for microfluidic systems and biosensors and can be effectively utilized in diagnostic, forensic, and life science research. The nanostructure of the SERS substrates ensures that signals are evenly distributed across the entire active surface, guaranteeing the reproducibility and reliability of the obtained results.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
To meet the different needs of research, Amerigo Scientific offers two types of active surfaces - hydrophilic and hydrophobic substrates, each providing specificity to the analyzed samples. While the hydrophilic substrates perform exceptionally well with aqueous solutions and are specifically tailored for life science and medical research, the hydrophobic substrates are perfect for alcohol-based solutions. It&amp;#039;s worth noting that hydrophobic substrates can also be used with aqueous solutions, but it&amp;#039;s recommended to immerse them in 70% ethanol beforehand. In the applications of Raman-based bacteria identification, cancer research, explosives detection in biological samples, identification of medicines, and chemical analysis, Amerigo Scientific&amp;#039;s SERS substrates boast several distinctive features that set them apart in the industry with&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Unparalleled Sensitivity: With an exceptional signal enhancement, Amerigo Scientific&amp;#039;s SERS substrates enable enhanced detection of even the most challenging samples and trace amounts of analytes.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Stability and Consistency: Developed using a rigorous manufacturing process, their SERS Substrates ensure consistent performance, minimizing batch-to-batch variations.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Versatility: Amerigo Scientific offers a variety of SERS Substrates suitable for various sample types and conditions, accommodating diverse research needs.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Amerigo Scientific&amp;#039;s &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/sers-substrates.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/sers-substrates.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;SERS substrates&amp;lt;/a&amp;gt; have been meticulously engineered to provide unrivaled performance. The cutting-edge manufacturing process guarantees a highly reproducible and uniform substrate, ensuring consistent results for every experiment. The proprietary nanostructures embedded in the substrate surface amplify Raman signals by orders of magnitude, unlocking new levels of sensitivity and enabling scientists to explore even the most challenging samples.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Amerigo Scientific&amp;lt;br /&amp;gt;
Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation to all companies and institutions in the branch of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers&amp;#039; questions or concerns and are always ready to provide individualized customer service of high standards.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Phoebe Davis&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1380762&amp;quot;&amp;gt;Click to Email Phoebe Davis&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.amerigoscientific.com/&amp;quot;&amp;gt;https://www.amerigoscientific.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1380762&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Ace Neuroscience Launches Drug Development Services for Stroke and Psychiatric Disorders</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-12-06T10:50:00-06:00</published>
    <updated>2023-12-06T10:50:00-06:00</updated>
    <author>
      <name>Ace Neuroscience</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 12/06/2023 -- Ace Neuroscience, a preclinical CRO service provider engaged in the research of stroke and antipsychotic drug development, has announced the launch of its drug development services for stroke and psychiatric disorders. The company aims to leverage its expertise and cutting-edge technology to develop innovative treatments for these conditions.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Stroke is a leading cause of disability and death worldwide, with limited treatment options available. Ace Neuroscience intends to closely work with global pharmaceutical and biotechnology partners to develop novel drugs that target the underlying mechanisms of stroke, with the goal of providing more effective and targeted treatments for patients. Based on its extensive research experience and advanced preclinical drug study platform, Ace Neuroscience provides comprehensive services for the &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.advaneuro.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.advaneuro.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;stroke therapy development&amp;lt;/a&amp;gt; in areas including but not limited to the development of small molecule drugs, stem cell therapies, gut microbiota therapies, therapeutic antibody therapies, exosome therapies, and UCHL1-based therapies. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
In addition to stroke, Ace Neuroscience is also engaged in the research of psychiatric disorders, such as depression and schizophrenia. These conditions affect millions of people globally and often have a significant impact on their quality of life. By leveraging specialized technologies and advanced platforms, Ace Neuroscience helps researchers explore the mysteries of mental illness and expedite &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.advaneuro.com/antipsychotics/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.advaneuro.com/antipsychotics/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;antipsychotic drug development&amp;lt;/a&amp;gt; through hit discovery, lead discovery, lead optimization, and candidate identification. From the protocol design to project completion, their gifted experts combine comprehensive anti-psychotic drug discovery expertise with an unparalleled range of capabilities in targets, platforms, and therapeutics, all to deliver scientific depth and breadth through data and insights clients can trust. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
As a customer-focused preclinical CRO, Ace Neuroscience is committed to accelerating the stroke research process, helping scholars to complete their research projects faster and more successfully. The launch of drug development services for stroke and psychiatric disorders marks a significant step forward in the field of neuroscience. By integrating cutting-edge technology, extensive research capabilities, and a focus on unmet medical needs, the company aims to make a meaningful impact on scientific research for these conditions. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Ace Neuroscience&amp;lt;br /&amp;gt;
Ace Neuroscience is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate antipsychotic drug development and stroke research. Over the years, the company has collaborated with many pharmaceutical and biotechnology companies by offering comprehensive drug development services to help researchers avoid potential hurdles and accelerate their efforts.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Daisy Mostert&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1380764&amp;quot;&amp;gt;Click to Email Daisy Mostert&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.advaneuro.com/&amp;quot;&amp;gt;https://www.advaneuro.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1380764&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Amerigo Scientific Unveils CRISPR/Cas Enzymes to Expand the CRISPR Toolbox</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-10-12T11:00:00-05:00</published>
    <updated>2023-10-12T11:00:00-05:00</updated>
    <author>
      <name>Amerigo Scientific</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 10/12/2023 -- Amerigo Scientific, as a distributor focused on providing critical products and services to biomedical and life science communities, announced the release of a groundbreaking selection of &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/class-2-crispr-cas-enzymes.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/class-2-crispr-cas-enzymes.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;CRISPR/Cas enzymes&amp;lt;/a&amp;gt; to its extensive life science portfolio, aimed at further expanding the vast potential of the CRISPR toolbox. This addition brings cutting-edge genetic editing tools to scientists and researchers in a variety of fields.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated) technology revolutionized the field of genetic engineering with its ability to edit DNA with remarkable precision. This technology has found vast applications in numerous scientific disciplines, ranging from agricultural biotechnology to therapeutic development, and has proven instrumental in solving complex genetic challenges.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Recognizing the unmet needs of the scientific community, Amerigo Scientific offers a comprehensive collection of CRISPR/Cas enzymes from global manufacturers covering all the core biological research areas. These effective enzymes promise to unlock an array of previously unattainable possibilities and drive pioneering breakthroughs in genetic research.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Among these CRISPR/Cas enzymes, &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/spcas9-nuclease-item-401215.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/spcas9-nuclease-item-401215.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;SpCas9 nuclease&amp;lt;/a&amp;gt; is a DNA endonuclease guided by crRNA and tracrRNA (or sgRNA alone), which is derived from S. pyogenes. SpCas9 specifically recognizes and cleaves dsDNA targets in a PAM (NGG)-dependent manner. The cleavage site of Cas9 in the target sequence is 3 bps away from the PAM site. In addition, studies have found that SpCas9 can specifically cleave ssDNA or ssRNA in the presence of DNA PAMmer sequences and can also be used in in vitro experiments for cleaving target DNA and cloning target fragments.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Featuring an assortment of highly configurable enzymes, Amerigo Scientific&amp;#039;s CRISPR/Cas enzymes empower researchers to precisely target specific genes, facilitating more accurate manipulation and modification of genetic material. The enzymes&amp;#039; unique characteristics make them particularly valuable for applications such as knockout studies, gene therapy development, precision agriculture, and countless other genetic engineering endeavors.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Amerigo Scientific&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.amerigoscientific.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.amerigoscientific.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Amerigo Scientific&amp;lt;/a&amp;gt;, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation to all companies and institutions in the branch of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers&amp;#039; questions or concerns and are always ready to provide individualized customer service of high standards.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Phoebe Davis&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1379021&amp;quot;&amp;gt;Click to Email Phoebe Davis&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.amerigoscientific.com/&amp;quot;&amp;gt;https://www.amerigoscientific.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1379021&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">NutriKane Set to Break Into the U.S. Market with a Range of Natural, Science-Backed Products Designed to Improve Health &amp; Wellness</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-09-07T11:20:00-05:00</published>
    <updated>2023-09-07T11:20:00-05:00</updated>
    <author>
      <name>NutriKane</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Boca Raton, FL -- (ReleaseWire) -- 09/07/2023 -- NutriKane, the pioneer in plant-based health products with over a decade of research and success, is excited to announce its upcoming launch in the United States. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Offering an impressive lineup of products, including NutriKane D, NutriKane R, NutriKane I, and NutriKane J, the company aims to enhance the health and wellness of Americans, specifically targeting those seeking natural methods to prevent or manage chronic health conditions.&amp;lt;br /&amp;gt;
The genesis of NutriKane dates back to 2011, with the company&amp;#039;s vision grounded in the belief that natural products, backed by rigorous science, can be transformative. Their journey began with extensive research and trialing plant-based ingredients, leading to the development of products that don&amp;#039;t just work but also taste good.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Michael Stovin-Bradford, Marketing &amp;amp; Sales Director at NutriKane, expressed his enthusiasm: &amp;quot;We are excited to introduce NutriKane to the U.S. market. Our products are a testament to our dedication to combining nature with science. They provide a wide range of the body&amp;#039;s nutritional needs, ensuring consumers experience tangible health benefits.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
According to the company, it&amp;#039;s their unique process technology, the intricate combination of ingredients, and the extensive research behind each ingredient are what sets NutriKane apart in the vast health product landscape. NutriKane&amp;#039;s products are natural, backed by science, and have shown effects, generally within two weeks of use. With a commitment to sustainability, 92% of NutriKane&amp;#039;s ingredients are sustainably sourced, and their key ingredients can often be traced back to the individual farmer and field.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Rod Lewis, CEO of NutriKane and a seasoned executive with three decades of experience in nurturing small, emerging companies, commented: &amp;quot;I&amp;#039;ve spent 12 years with NutriKane and can confidently say our products stand head and shoulders above the rest. Our commitment to the Food-as-Medicine approach and the unwavering support from the Australian government underscores our mission to make the world a healthier place.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Dr. Malcolm Ball, with 25 years in high-end technical product development and 12 years with NutriKane, has been pivotal in commercializing the product line. His expertise has played a vital role in ensuring that NutriKane&amp;#039;s products stand out in a crowded market, consistently delivering on their promise.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Positive feedback has been consistent since NutriKane&amp;#039;s initial launch, with many users observing swift health improvements. Notably, the products have undergone successful clinical trials at the Royal Melbourne Hospital in Melbourne, Australia, further cementing their efficacy.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Furthermore, NutriKane&amp;#039;s commitment to sustainability doesn&amp;#039;t stop at the products. Their key suppliers, recognized for their sustainable footprints, are supported by the Australian government.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
With its launch in the U.S., NutriKane hopes to replicate its success and continue its mission of improving health through natural means.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information about NutriKane and their range of products, please visit &amp;lt;a href=&amp;quot;http://www.nutrikane.com.au&amp;quot;&amp;gt;&amp;lt;a href=&amp;quot;http://www.nutrikane.com.au&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.nutrikane.com.au&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. This press release is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a healthcare professional. The news site hosting this press release is not associated with MediKane Holdings Ltd. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Kayla Zadel&amp;lt;br /&amp;gt;Director of Communications&amp;lt;br /&amp;gt;InHealth Media&amp;lt;br /&amp;gt;Telephone: 1-561-544-0719&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1377704&amp;quot;&amp;gt;Click to Email Kayla Zadel&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://inhealthmedia.com/&amp;quot;&amp;gt;https://inhealthmedia.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1377704&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Liver Medic Is Dedicated to Helping with the Negative Effects of Bad Gut Health</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2023-03-02T10:18:00-06:00</published>
    <updated>2023-03-02T10:18:00-06:00</updated>
    <author>
      <name>Liver Medic</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=375050&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Coral Springs, FL -- (ReleaseWire) -- 03/02/2023 -- Liver Medic, focused on the most efficacious and cleanest ways to formulate products to maximize healing only nature can provide, has been working on helping as many people as possible correct their bad gut health. Getting off track with food choices isn&amp;#039;t a big deal when it only happens once in a while, but realistically everyone could do better in this department. Fortunately, there are natural options that can help from Liver Medic.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Bad gut health can manifest itself in a number of ways. For example, a person&amp;#039;s mood can be dramatically affected by the foods that they eat. When people have bad gut health they are more likely to suffer from depression, anxiety, and fatigue. This often comes from consuming a lot of processed foods instead of whole foods.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Bad gut health can also manifest with digestive issues such as constipation, diarrhea, and even irritable bowel syndrome. IBS symptoms include gas, abdominal pain, excessive bloating, diarrhea, and constipation. Diet is one of the major contributors to the development of irritable bowel syndrome, so it makes sense that improving one&amp;#039;s diet will transform a bad gut health situation into a better environment.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Bad gut health can also affect a person&amp;#039;s sleep as well. Instead of getting restful sleep, people suffering from bad gut health can deal with insomnia, or not being able to sleep through the night. And then they will have things that contain caffeine and not make as good of food decisions the next day, and the situation continues.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The good news is that bad gut health can be repaired, and everyone can enjoy better health every day with the natural supplements from Liver Medic. They have several supplements that will help to correct the issues over time, including Candida Complex, &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.livermedic.com/products/leaky-gut-repair-powder/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.livermedic.com/products/leaky-gut-repair-powder/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Leaky Gut Repair&amp;lt;/a&amp;gt;, Hepatiben, as well as Digest Harmony. These will not be all taken at the same time, but their team will recommend a regimen that, over time, will reverse the bad gut health users have been experiencing and lead them to better health, better sleep, and a better life. Contact their team today to learn more about how to remedy bad gut health.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Liver Medic&amp;lt;br /&amp;gt;
Liver Medic exists to help people heal from today&amp;#039;s common ailments with nature&amp;#039;s remedies. They offer a number of different natural supplements. Learn more at their website: &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.livermedic.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.livermedic.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;&amp;lt;a href=&amp;quot;http://www.livermedic.com&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.livermedic.com&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Press Manager&amp;lt;br /&amp;gt;Telephone: 1-800-387-2278&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1371189&amp;quot;&amp;gt;Click to Email Press Manager&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.livermedic.com/&amp;quot;&amp;gt;https://www.livermedic.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1371189&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=375050" rel="enclosure" title="Logo for Liver Medic"/>
  </entry>
  <entry>
    <title type="text">Announcing Druglike – A Web3 Drug Discovery Platform</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2022-10-12T11:45:02-05:00</published>
    <updated>2022-10-12T11:45:02-05:00</updated>
    <author>
      <name>Druglike</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=355309&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;New York, NY -- (ReleaseWire) -- 07/25/2022 -- Druglike, a Web3 drug discovery software platform co-founded by Martin Shkreli, today released a demo, website, and whitepaper detailing its efforts to democratize the costs, access, and rewards of computational drug discovery.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;We started Druglike because in our experience, traditional drug discovery software is too difficult and expensive to use,&amp;quot; said Martin Shkreli, Co-Founder of Druglike. &amp;quot;Druglike will remove barriers to early-stage drug discovery, increase innovation and allow a broader group of contributors to share the rewards.&amp;quot; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Shkreli added: &amp;quot;Underserved and underfunded communities, such as those focused on rare diseases or in developing markets, will also benefit from access to these tools.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Druglike is building a decentralized compute network which provides resources for anyone looking to start or contribute to early-stage drug discovery projects. Unlike competitors, Druglike will be web-based and completely free to use. Druglike will soon release a web-based suite for target identification, drug design, and tools for both constructing and running large-scale virtual screening workflows.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Druglike&amp;#039;s ability to revolutionize drug discovery is enabled by Web3 technology.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Proof-of-Optimization, a novel blockchain consensus mechanism described in the whitepaper,  plans to solve computational chemistry problems at a cost competitive with that of standard on premises and cloud computing. Compute contributors can run both solver and validator nodes powering industrial-scale virtual screening campaigns in exchange for $MSI, the platform&amp;#039;s official token. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;For the first time, any computer or phone with access to the web might be responsible and rewarded for discovering the next breakthrough medicine,&amp;quot; said Shkreli, Druglike Co-Founder. &amp;quot;We will disrupt the economics of the drug business by allowing a wide pool of innovators and contributors, rather than only pharmaceutical giants, to profit from drug discovery.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Current in silico software is only accessible to large pharmaceutical companies willing to pay obnoxious licensing fees. Students in every country no matter their university, startup companies to Fortune 500s, and even dedicated hobbyists will all have the same opportunity to design new molecules to change the future of drug discovery,&amp;quot; said Shkreli, co-founder of Druglike. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Druglike, a decentralized science (DeSci) drug discovery Web3 platform founded in 2022, seeks to democratize and disrupt the current in silico computational chemistry software industry by offering pharmaceutical researchers, students, and activists access to computational resources and a marketplace to securely work together creating new molecules and intellectual property rights. Druglike uses Proof-of-Optimization, a novel blockchain consensus mechanism, to secure the integrity of the research shared, and Non-Fungible Token (NFT) technology to secure IP rights in the earliest stages of new molecule creation. For more information about Druglike please refer to the white paper here: druglike.com&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
SAFE HARBOR STATEMENT&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The information provided in this press release pertaining to Druglike (&amp;quot;the Company&amp;quot;), its business assets, strategy, and operations, is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any assets related to the Company. Information contained in this press release should not be relied upon as advice to buy or do anything. Druglike reserves the right to amend or replace the information contained herein, in part or entirely, at any time. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed in this press release.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Druglike is a blockchain/Web3 software company and not a pharmaceutical company. Druglike is not engaged in pharmaceutical research or drug development.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Statements in this communication that are not historical facts are forward-looking statements that reflect the Company&amp;#039;s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of the Company, including its ability to realize the benefits from our operating model or  successfully pursue stated initiatives.  All statements other than historical facts may be forward-looking statements and can be identified by words such as &amp;quot;anticipate,&amp;quot; &amp;quot;believe,&amp;quot; &amp;quot;could,&amp;quot; &amp;quot;design,&amp;quot; &amp;quot;estimate,&amp;quot; &amp;quot;expect,&amp;quot; &amp;quot;forecast,&amp;quot; &amp;quot;goal,&amp;quot; &amp;quot;guidance,&amp;quot; &amp;quot;imply,&amp;quot; &amp;quot;intend,&amp;quot; &amp;quot;may&amp;quot;, &amp;quot;objective,&amp;quot; &amp;quot;opportunity,&amp;quot; &amp;quot;outlook,&amp;quot; &amp;quot;plan,&amp;quot; &amp;quot;position,&amp;quot; &amp;quot;potential,&amp;quot; &amp;quot;predict,&amp;quot; &amp;quot;project,&amp;quot; &amp;quot;prospective,&amp;quot; &amp;quot;pursue,&amp;quot; &amp;quot;seek,&amp;quot; &amp;quot;should,&amp;quot; &amp;quot;strategy,&amp;quot; &amp;quot;target,&amp;quot; &amp;quot;would,&amp;quot; &amp;quot;will,&amp;quot; &amp;quot;aim&amp;quot; or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of the Company.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
CONTACT INFORMATION:&amp;lt;br /&amp;gt;
pr@druglike.com&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Twitter: &amp;lt;a href=&amp;quot;https://twitter.com/druglike_io&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;https://twitter.com/druglike_io&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Kevin McSheehan&amp;lt;br /&amp;gt;Advisor&amp;lt;br /&amp;gt;Druglike&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1361234&amp;quot;&amp;gt;Click to Email Kevin McSheehan&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://druglike.com&amp;quot;&amp;gt;https://druglike.com&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1361234&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=355309" rel="enclosure" title="Logo for Druglike"/>
  </entry>
  <entry>
    <title type="text">Psoriasis Drugs Market Is Predicted to Progress at a CAGR of 6.5% to Reach a Valuation of US$ 21.48 Bn by 2031</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2022-03-31T11:59:04-05:00</published>
    <updated>2022-03-31T11:59:04-05:00</updated>
    <author>
      <name>Persistence Market Research</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;New york, NY -- (ReleaseWire) -- 03/31/2022 -- New York:  Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 &amp;ndash; 3% of the population globally.&amp;lt;br /&amp;gt;
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/market-research/psoriasis-drugs-market.asp&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/market-research/psoriasis-drugs-market.asp&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;psoriasis drugs market&amp;lt;/a&amp;gt; in 2021, with the market estimated to expand at a CAGR of nearly 6.5% over the next ten years.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
An array of agents exist for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis typically receive topical treatments that modulate gene transcription, promote keratinocyte differentiation, and inhibit cell proliferation.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action. Psoriasis is linked with a number of medical conditions inclusive of psoriatic arthritis, depression, and cardio metabolic syndrome. The most commonly occurring form of psoriasis is chronic plaque.&amp;lt;br /&amp;gt;
Common treatment methods of psoriasis include topical administration of vitamin D analogues, glucocorticoids, and phototherapy. Moderate to severe psoriasis often calls for systemic treatment.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Prevalence of psoriasis has displayed a growing trend over the past decade. Rising awareness initiatives regarding psoriasis disease and its management &amp;amp; treatment options, increasing reimbursement support, and growing research &amp;amp; development with the adoption of biologics and biosimilars are some of the factors responsible for impacting the psoriasis drugs market and aiding sales growth.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Request for sample report: &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/samples/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/samples/25102&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/samples/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/samples/25102&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Key Takeaways from Market Study&amp;lt;br /&amp;gt;
-	Topical products are expected to continue holding over one-third market value share through 2031, primarily because of clinically approved topical ointments, foams, and creams available for the management of inflammation and rash due to psoriasis.&amp;lt;br /&amp;gt;
-	Efficiency of corticosteroids for skin irritability and inflammation makes corticosteroid the leading segment with over 34% of revenue share in 2021.&amp;lt;br /&amp;gt;
-	Easy availability of psoriasis drugs in hospital pharmacies and large distribution networks of hospital chains make it the largest segment, with more than 39% market share.&amp;lt;br /&amp;gt;
-	Plaque psoriasis is the most commonly occurring autoimmune disease, accounting for a revenue share of around 85% in 2021.&amp;lt;br /&amp;gt;
-	Presence of a large number of manufacturers, rising public awareness, and easy availability of psoriasis drugs and treatment options make North America the leading regional market with over 27% market share in 2021.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Know the methodology of report: &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/methodology/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/methodology/25102&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/methodology/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/methodology/25102&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Growing adoption of combination therapy and favourable reimbursement support for psoriasis to drive market growth,&amp;quot; says an analyst of Persistence Market Research.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Market Competition&amp;lt;br /&amp;gt;
Companies such as Amgen and Sun Pharma have been strongly working toward the development of an extensive clinical pipeline and manufacturing of new product lines for the treatment of psoriasis.&amp;lt;br /&amp;gt;
-	In December 2021, Amgen announced positive top-line results from the Otezla&amp;reg; (apremilast) Phase 3 DISCREET study in moderate to severe genital psoriasis.&amp;lt;br /&amp;gt;
-	In September 2020, Sun Pharma announced the launch of ILUMYA&amp;reg; (tildrakizumab) for the treatment of plaque psoriasis, in Japan.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Similarly, other psoriasis drug manufacturers are also trying to maintain and strengthen their portfolios through collaborations with local players or distribution partners. All such recent developments related to companies manufacturing psoriasis drugs have been tracked by the team at Persistence Market Research, which are available in the full report.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Key companies operating in the psoriasis drugs market include Janssen Biotech Inc, Novartis International Ltd., Amgen Inc, Pfizer Inc., Takeda Pharmaceutical Company Ltd. Merck &amp;amp; Co, Inc., Abb Vie Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, and Sun Pharmaceutical Industries Ltd.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Get full access of report: &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/checkout/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/checkout/25102&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/checkout/25102&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/checkout/25102&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
What Does the Report Cover?&amp;lt;br /&amp;gt;
Persistence Market Research offers a unique perspective and actionable insights on the psoriasis drugs market in its latest study, presenting historical demand assessment of 2016 &amp;ndash; 2021 and projections for 2022 &amp;ndash; 2031.&amp;lt;br /&amp;gt;
The research study is based on the product (topical, oral, and injectable), drug class (interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitor), distribution channel (hospital pharmacies, retail pharmacies, and e-Commerce), and indication (guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and plaque psoriasis), across seven key regions of the world.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Related Reports:&amp;lt;br /&amp;gt;
-	&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/market-research/plaque-psoriasis-treatment-market.asp&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/market-research/plaque-psoriasis-treatment-market.asp&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Plaque Psoriasis Treatment Market&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;
-	&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/market-research/systemic-psoriasis-therapeutics-market.asp&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/market-research/systemic-psoriasis-therapeutics-market.asp&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Systemic Psoriasis Therapeutics Market&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;
-	&amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.persistencemarketresearch.com/market-research/chronic-plaque-psoriasis-therapeutics-market.asp&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.persistencemarketresearch.com/market-research/chronic-plaque-psoriasis-therapeutics-market.asp&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Chronic Plaque Psoriasis Therapeutics Market&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Persistence MR&amp;lt;br /&amp;gt;Telephone: 1-646-568-7751&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1353995&amp;quot;&amp;gt;Click to Email Persistence MR&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.persistencemarketresearch.com/&amp;quot;&amp;gt;https://www.persistencemarketresearch.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1353995&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Enzolytics IPF Immune Will Soon Be Available to American Consumers</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2022-02-22T12:10:03-06:00</published>
    <updated>2022-02-22T12:10:03-06:00</updated>
    <author>
      <name>Enzolytics, Inc</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=336936&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;Science-Backed Immune Booster is Coming in 2022.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Boca Raton, FL -- (ReleaseWire) -- 02/22/2022 -- Enzolytics IPF Immune&amp;trade;, an immune modulator, will be available later this year to American consumers, who, during the pandemic, have been seeking out immunity booster supplements to give themselves a health advantage.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Even before COVID-19, infections, such as the regular flu virus, weakened the immune system. Lifestyle choices, such as an inadequate diet, smoking, and alcohol consumption, also affect the immune system.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Enzolytics IPF Immune&amp;trade; strengthens the body&amp;#039;s immune system,&amp;quot; said &amp;lt;a href=&amp;quot;https://enzolytics.com/about-enzolytics-inc/&amp;quot;&amp;gt;Charles S. Cotropia&amp;lt;/a&amp;gt;, CEO of &amp;lt;a href=&amp;quot;https://enzolytics.com/infectious-disease-therapeutics/&amp;quot;&amp;gt;Enzolytics, Inc.&amp;lt;/a&amp;gt;, a Texas biotech company. &amp;quot;COVID-19 made everyone aware and concerned about their immune system.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Since the pandemic started, sales for immune booster supplements have skyrocketed. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Now, consumers have a science-backed immune modulator to keep their bodies operating optimally,&amp;quot; he added.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Our immune modulator helps fortify the immune system against infections,&amp;quot; said Harry Zhabilov, the Company CSO. &amp;quot;Enzolytics&amp;#039; research and development team spent more than a decade developing Enzolytics IPF Immune&amp;trade;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;Enzolytics IPF Immune&amp;trade; is a liquid nutritional supplement that acts to strengthen the body&amp;#039;s natural defenses,&amp;quot; Mr. Zhabilov added. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Enzolytics IPF Immune&amp;trade;, which is gluten-free, is taken orally for two consecutive days per week for eight consecutive weeks.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;You can take Enzolytics IPF Immune&amp;trade; to give your immune system a boost to ward off many infections that your body is confronted with year-round,&amp;quot; he added.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, email pr@nutrapr.com or visit &amp;lt;a href=&amp;quot;https://enzolytics.com/&amp;quot;&amp;gt;enzolytics.com&amp;lt;/a&amp;gt;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Enzolytics, Inc.&amp;lt;br /&amp;gt;
Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune&amp;trade;, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases, including monoclonal antibodies for treating COVID-19 and HIV, and anti-cancer therapeutics.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Company Contact:&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Enzolytics, Inc.&amp;lt;br /&amp;gt;
2000 North Central Expressway&amp;lt;br /&amp;gt;
Plano, TX 75074&amp;lt;br /&amp;gt;
And&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Research Center&amp;lt;br /&amp;gt;
Enzolytics, Inc.&amp;lt;br /&amp;gt;
Texas A&amp;amp;M University&amp;lt;br /&amp;gt;
Institute for Preclinical Studies&amp;lt;br /&amp;gt;
College Station, TX 77843-44&amp;lt;br /&amp;gt;
SOURCE: Enzolytics, Inc.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Robert Grant&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1353664&amp;quot;&amp;gt;Click to Email Robert Grant&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://enzolytics.com/&amp;quot;&amp;gt;https://enzolytics.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1353664&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=336936" rel="enclosure" title="Logo for Enzolytics, Inc"/>
  </entry>
  <entry>
    <title type="text">Herboxa Developed the Purest and All Natural Formula for Lung Support</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2022-01-12T03:59:02-06:00</published>
    <updated>2022-01-12T03:59:02-06:00</updated>
    <author>
      <name>Herboxa Nutrition</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=437521&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;D&amp;uuml;sseldorf, Germany -- (ReleaseWire) -- 01/12/2022 -- Staying healthy is a task that is performed by the combination of the kind of lifestyle we live, the kind of food we eat and how we help boost our system with the supplements we take to make our body system (both internal and external) stronger.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The respiratory system is a delicate part of the body. It is made up of the lungs, and the airways from the mouth through the nose, throat (pharynx), voice box (larynx), windpipe (trachea) etc. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Keeping our respiratory health at a top-level goes beyond living a healthy lifestyle, and that&amp;#039;s why there is &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.herboxa.com/herboxa-lungwort&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.herboxa.com/herboxa-lungwort&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Herboxa Lungwort&amp;lt;/a&amp;gt; to boost your respiratory health.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Herboxa Lungwort contains vital ingredients that can help boost  respiratory system health as it contains a natural plant, the lungwort leaf, which is known to be effective against cold and respiratory conditions like coughs and catarrh.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Why Herboxa Lungwort?&amp;lt;br /&amp;gt;
Herboxa Lungwort promotes normal lung function by helping in the elimination of toxins while also detoxing the lungs. This revitalizes the body, along with the respiratory organs, and all these are done by a herbal component that is gluten-free.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
So if you have persistent respiratory problems or breathing issues, Herboxa Lungwort has the needed nutritional supplements and vitamins to help solve respiratory problems involving the lungs and nose, while also providing the needed support to other linked internal organs, stimulating them for maximum performance that gives you a healthy living.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
How Does Herboxa Lungwort Boost Respiratory Health?&amp;lt;br /&amp;gt;
Herboxa Lungwort stimulates the respiratory organs by soothing any irritation appearing in the lungs. By doing so, the lungs will be in good shape to carry out their normal function.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Similarly, the throat gets soothing relief because Herboxa Lungwort is known to help with breathing conditions, and also provides relief for some internal health issues.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Herboxa Lungwort should be applied based on its description. However, users have reported positive changes in their respiratory health within just a few days of prescription. There are numerous positive reviews on the effectiveness of the products from all over the world.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Adults can take 2 or 3 capsules daily preferably with a meal. Furthermore, Herboxa Lungwort is a safe herb to consume with no known side effects or drawbacks. It is gluten-free for those who are not tolerant to gluten, while vegans can also benefit from this plant-based supplement.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Official Website - &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.herboxa.com&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.herboxa.com&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Herboxa Nutrition&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Maia Wilson&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1351220&amp;quot;&amp;gt;Click to Email Maia Wilson&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.herboxa.com/&amp;quot;&amp;gt;https://www.herboxa.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1351220&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=437521" rel="enclosure" title="Logo for Herboxa Nutrition"/>
  </entry>
  <entry>
    <title type="text">Compounding Pharmacy, ABC Compounding Pharmacy Launches New Resource Page for Patients</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2021-11-24T11:10:03-06:00</published>
    <updated>2021-11-24T11:10:03-06:00</updated>
    <author>
      <name>ABC Compounding Pharmacy</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=90485&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;Compounding Pharmacy ABC Compounding Pharmacy Launches New Resource Page for Patients. ABC Compounding Pharmacy is a world-renowned compound medicine pharmacy led by a team of trusted and reliable pharmacists, technicians, and chemists with extensive experience in the industry. Over the years, ABC Compounding Pharmacy has established itself as the go-to compounding pharmacy specializing in a myriad of medications.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Encino, CA -- (ReleaseWire) -- 11/24/2021 -- &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Compounding Pharmacy&amp;lt;/a&amp;gt; ABC Compounding Pharmacy Launches New Resource Page for Patients. ABC Compounding Pharmacy is a world-renowned compound medicine pharmacy led by a team of trusted and reliable pharmacists, technicians, and chemists with extensive experience in the industry. Over the years, ABC Compounding Pharmacy has established itself as the go-to &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;compounding pharmacy&amp;lt;/a&amp;gt; specializing in a myriad of medications. Committed to providing unmatched quality and service to each and every patient, you can expect the very best forms of compound medicine specific to you and your needs. ABC Compounding Medicine is dedicated to exceeding their patients&amp;#039; expectations and their goal is to provide customized compound medication catered to each and every individual resulting in effective outcomes. Based in Encino, ABC Compounding Pharmacy is located at 16311 Ventura Blvd, Encino, CA 91436 and can be reached at (818) 783-0422. To learn more about ABC Compounding Pharmacy, visit their website &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
ABC Compounding Pharmacy launched their new resource page for patients, providing valuable information for patients interested in compound medicines, answering any questions or concerns that they may have. ABC Compounding Pharmacy has established itself as a world-renowned compound medicine pharmacy, specializing in a myriad of medicines including but not limited to, pain management, sports medicine, hormone therapy, dermatology, cosmeceuticals, animal and veterinary medicine, and much more. Led by a team of trusted and reliable pharmacists, technicians, and chemists, you can count on the team at ABC Compounding Pharmacy to provide patients with unmatched services. In fact, the compounding pharmacy has become the go-to solution for patients in need of customized medications specific to their needs. ABC Compounding Pharmacy is dedicated to exceeding its patients&amp;#039; expectations and its goal is to provide customized compound medication catered to each and every individual. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
One of the many elements that set compounding pharmacies apart from retail pharmacies is the fact that compounding pharmacies specialize in creating customized medications for patients using base ingredients, as opposed to pre-mixed formulas. This means that compound pharmacists are able to curate highly effective medications using base drugs and combining them specifically for each patient&amp;#039;s needs. Some of the factors considered when creating customized medications include each patient&amp;#039;s height, weight, gender, age, condition, as well as a number of other elements. When factoring in these crucial elements, it reduces side effects and improves each patient&amp;#039;s overall results.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Because base ingredients are used in compound pharmacies, the dosages are usually adjusted in smaller rations as opposed to commercially-made options in retail pharmacies.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Compound medications are an excellent alternative to traditional pharmaceutical medicines due to the fact that no preset formulas or dosages are used. Every patient is different, so to ensure the most effective results, you can imagine that each patient requires different dosages, formulas, and other factors in order to achieve optimal results. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Additionally, the benefits of compound medications don&amp;#039;t just stop there. With compounding medicine, patients can experience optimal results as the medication is catered to you--as an individual--as opposed to a mass of people with the same or similar condition. Here are some other benefits that patients can experience from compound medications:&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
- Personalized dosages&amp;lt;br /&amp;gt;
- Different configurations of the same medications&amp;lt;br /&amp;gt;
- Specialty medications&amp;lt;br /&amp;gt;
- Access to discontinued medications&amp;lt;br /&amp;gt;
- Access to medications that have been sold out due to high demand&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
As you can imagine, there are a great number of benefits to compound medications. If you are interested in discovering a customized solution for your condition, then having a compounding pharmacy that you can rely on when you need them most is absolutely essential. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
To learn more about ABC Compounding Pharmacy, you can visit their website https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt; or you can reach their office at (818) 783-0422. Located at 16311 Ventura Blvd, Encino, CA 91436, ABC Compounding Pharmacy is committed to providing the best service for every patient.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About ABC Compounding Pharmacy &amp;lt;br /&amp;gt;
The team at ABC Compounding Pharmacy has extensive experience providing customized solutions for patients in need of specialty medications with real results. As a team of trusted and reliable pharmacists, technicians, and chemists with years of experience, you can count on the team at ABC Compounding Pharmacy to provide you with the medications and results you need. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
If you are searching for a compounding pharmacy that can provide you with personalized dosages, different forms of the same medications, specialty medications, access to discontinued medications, or access to medications that have been sold out due to high demand, our team is here to help. From dermatology to hormone therapy, to pain management and so much more, the team at ABC Compounding Pharmacy has the right solution for you.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Based in Encino, ABC Compounding Pharmacy is located at 16311 Ventura Blvd, Encino, CA 91436 and can be reached at (818) 783-0422. To learn more about ABC Compounding Pharmacy, visit their website &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.abccompoundingpharmacy.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Dana Smith&amp;lt;br /&amp;gt;Telephone: 1-818-783-0422&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1349411&amp;quot;&amp;gt;Click to Email Dana Smith&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.abccompoundingpharmacy.com/&amp;quot;&amp;gt;https://www.abccompoundingpharmacy.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1349411&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=90485" rel="enclosure" title="Logo for ABC Compounding Pharmacy"/>
  </entry>
  <entry>
    <title type="text">Newly Launched Podcast Offers Medical Professionals an Intriguing Blend of Science, Tales from the Trenches, &amp; Free CME</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2021-06-30T13:14:00-05:00</published>
    <updated>2021-06-30T13:14:00-05:00</updated>
    <author>
      <name>Medavera</name>
    </author>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Springfield, MO -- (ReleaseWire) -- 06/30/2021 -- The search for an interesting and edifying medical podcast is over. The On Medical Grounds Podcast is available now at &amp;lt;a href=&amp;quot;http://www.onmedicalgrounds.com&amp;quot;&amp;gt;OnMedicalGrounds.com&amp;lt;/a&amp;gt;, Apple Podcasts, Spotify, Google Podcasts, and other major podcast platforms.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Hosted by Jill Sellers, PharmD, On Medical Grounds fills a void in the medical podcast space by serving up timely topics, interesting and authentic conversations, and intriguing interviews with medical experts and industry professionals. Select podcasts also offer free continuing medical education credits.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The podcast&amp;#039;s debut episodes include:&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
EPISODE 1: An Orthopedic Surgeon, A Bike Wreck, And Stopping the Cycle Of Opioid Abuse (Free CME) &amp;lt;br /&amp;gt;
This episode features an interview with Stephen Southworth, M.D., Orthopaedic Institute of North Mississippi on how he developed a protocol to improve perioperative pain management while reducing opioids.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
EPISODE 2: Seven Things To Know About Treating Hyponatremia (Free CME) &amp;lt;br /&amp;gt;
This episode features an interview with expert nephrologist and mountain climber, Biff Palmer, M.D., UT Southwestern Medical Center, on why Hyponatremia needs to be addressed and appropriately treated.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
EPISODE 3: How A Hospital CEO Prepared For A Pandemic &amp;lt;br /&amp;gt;
This episode features a conversation with Steve Edwards, president and CEO of Cox Health, (Springfield, MO) on what was going through his mind as it became evident that COVID-19 was becoming a deadly global pandemic, and how he leveraged lessons from the past, social media, and international connections to prepare for it.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Upcoming episodes will include the remarkable experience and recovery of a COVID-19 patient after 15 days on a ventilator, 21 days under sedation, and a total of 83 days in a COVID Rehab Unit, and the story of a family devastated by a rare disease and a sister&amp;#039;s hope to find a cure.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
On Medical Grounds is a production of Medavera,&amp;reg; a medical education program provider that focuses on creating exceptional learning opportunities for medical professionals. Medavera&amp;reg; identifies gaps in knowledge and care, methodically researches the subject matter, identifies top experts to guide the content, and utilizes groundbreaking formats to deliver stimulating and actionable medical education.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, contact Rachael Johnson at rachael@medavera.com or 417.890-9722 extension 2.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;http://www.onmedicalgrounds.com&amp;quot;&amp;gt;OnMedicalGrounds.com&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Rachael Johnson&amp;lt;br /&amp;gt;Telephone: 1-417-890-9722&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1342554&amp;quot;&amp;gt;Click to Email Rachael Johnson&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.medavera.com&amp;quot;&amp;gt;https://www.medavera.com&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1342554&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
  </entry>
  <entry>
    <title type="text">Outcomes and Risk Factors Associated with COVID-19 and Multiple Sclerosis Published in JAMA Neurology</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2021-03-22T09:15:00-05:00</published>
    <updated>2021-03-22T09:15:00-05:00</updated>
    <author>
      <name>The Consortium of Multiple Sclerosis Centers (CMSC)</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=79562&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Hackensack, NJ -- (ReleaseWire) -- 03/22/2021 -- An original investigation of the outcomes and risk factors associated with COVID-19 from a cross-section of multiple sclerosis patients from the COViMS North American registry was published online on March 19th in JAMA Neurology. Led by Amber Salter, PhD, this research of outcomes experienced by 1,626 people in the COViMS registry between April and December 2020 found these conclusions:&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
- Ambulation disability, older age, and Black race are associated with worse COVID-19 clinical course in a North American MS population. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
- Rituximab use, and recent treatment with corticosteroids, as well as risk factors known in the general population such as obesity and cardiovascular comorbidities were associated with worse COVID-19 clinical severity. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Knowledge of these risk factors may improve the management of patients with MS and COVID-19 by helping clinicians identify patients requiring more intense monitoring or COVID-19 treatment.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The COViMS Registry is a joint effort of the &amp;lt;a href=&amp;quot;http://www.mscare.org&amp;quot;&amp;gt;Consortium of Multiple Sclerosis Centers&amp;lt;/a&amp;gt;(CMSC), the National MS Society and the MS Society of Canada.  It was created early in the pandemic for health care professionals to report cases of COVID-19 infection in people with MS and related conditions. Its goal is to understand how people with MS fare on exposure to the virus and to identify factors that might be associated with COVID-19 outcomes.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Read &amp;quot;Outcomes and Risk Factors Associated with SARS-COV-2 Infection in a North American Registry of Patients with Multiple Sclerosis,&amp;quot; by Amber Salter, PhD, Robert J. Fox, MD, Scott D. Newsome, DO, June Halper, MSCN, David K. B. Li, MD, Pamela Kanellis, PhD, Kathleen Costello, MSCN, Bruce Bebo, PhD, Kottil Rammohan, MD, Gary R. Cutter, PhD, and Anne H. Cross, MD, published online March 19, 2021 in JAMA Neurology here: &amp;lt;a href=&amp;quot;https://jamanetwork.com/journals/jamaneurology/fullarticle/2777735&amp;quot;&amp;gt;&amp;lt;a href=&amp;quot;https://jamanetwork.com/journals/jamaneurology/fullarticle/2777735&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;https://jamanetwork.com/journals/jamaneurology/fullarticle/2777735&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
To obtain additional information about COViMS or to report a case of COVID-19, please visit &amp;lt;a href=&amp;quot;http://www.covims.org&amp;quot;&amp;gt;&amp;lt;a href=&amp;quot;http://www.covims.org&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.covims.org&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS (CMSC)&amp;lt;br /&amp;gt;
The CMSC includes a professional network of 13,500 healthcare clinicians and scientists worldwide. Its membership represents the full spectrum of MS healthcare professionals: physicians, nursing professionals, advanced practice clinicians, pharmacists, rehabilitation and mental health professionals, researchers, and patient advocates. The work of the CMSC directly influences the quality of care for hundreds of thousands of people living with MS.  For more information visit: &amp;lt;a href=&amp;quot;http://www.mscare.org&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.mscare.org&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Annie Scully&amp;lt;br /&amp;gt;Public Relations Consultant&amp;lt;br /&amp;gt;Consortium of Multiple Sclerosis Centers (CMSC)&amp;lt;br /&amp;gt;Telephone: 1-201-310-9252&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1332454&amp;quot;&amp;gt;Click to Email Annie Scully&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.mscare.org&amp;quot;&amp;gt;http://www.mscare.org&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1332454&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=79562" rel="enclosure" title="Logo for The Consortium of Multiple Sclerosis Centers (CMSC)"/>
  </entry>
  <entry>
    <title type="text">Frontida BioPharm, Inc. Launches CAT.one Testing to Support Abuse-Deterrent Product Development</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2021-01-13T08:00:00-06:00</published>
    <updated>2021-01-13T08:00:00-06:00</updated>
    <author>
      <name>Frontida BioPharm, Inc.</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=252063&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Philadelphia, PA -- (ReleaseWire) -- 01/13/2021 -- Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the launch of its new Category 1 (CAT.ONE&amp;trade;) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
To enable the launch of its CAT.ONE&amp;trade; services, Frontida has hired a team of industry-recognized scientists with a proven track record of success in performing FDA-compliant Category 1 laboratory-based manipulation and extraction studies to support the evaluation and NDA and ANDA regulatory submission of products designed with abuse-deterrent properties. The team joining Frontida - Dr. Eric Kinzler, Chris Altomare, Greg Gironda, and Amanda Camody - previously collaborated on the design and execution of over 60 such studies involving investigational and approved abuse-deterrent products currently prescribed in the USA. To support the team, Frontida has also acquired specialized product manipulation equipment uniquely designed to simulate various abuse techniques (such as chewing, smoking, and vaping) and essential to reproducibly perform Category 1 evaluations. Frontida will leverage its established expertise in analytical development and high-throughput sample processing to rapidly deliver results for these studies.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Ron Connolly, Frontida&amp;#039;s Executive Vice President of Business Development, Alliances and Regulatory Affairs, remarked, &amp;quot;Frontida&amp;#039;s team is excited to augment our product development expertise for clients seeking to develop and commercialize new abuse-deterrent products. The scientific leadership team we have brought on board to launch our new CAT.ONE&amp;trade; service offering has proven to be among the best in industry in designing and executing studies to demonstrate whether a product&amp;#039;s formulation attributes can reduce its potential for abuse. With the team&amp;#039;s proven track record and collective experience, we can quickly support the approval process, provide technical insight into how to incorporate abuse-deterrent properties into the formulation matrix, and help our clients navigate the regulatory and technical challenges of obtaining new approvals and product launches in important therapeutic categories. Coupled with our ability to commercially manufacture and package DEA-regulated products, Frontida can provide a high quality and reliable CDMO partnership to leading brand and generic pharmaceutical companies.&amp;quot; &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Frontida BioPharm, Inc.&amp;lt;br /&amp;gt;
Frontida BioPharm, Inc. is a U.S. based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. Our experts are dedicated to helping clients and partners reach the market as quickly and efficiently as possible. Frontida supports pharmaceutical companies in the development, scale-up, and commercial manufacturing of immediate and controlled-release oral solid dose, powder, and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Our 325,000+ sq. ft. manufacturing facilities located in Philadelphia, Pa. and Aurora, Ill. offer a comprehensive suite of solutions for the development and commercialization of prescription, OTC, Highly Potent Active compounds, Phase I through Phase III clinical trial materials, Fixed-dose Combination products, and DEA schedule II&amp;ndash;V products. Frontida is equipped with multiple world-class commercial packaging lines, capable of validated product serialization and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. Frontida has an annual capacity to manufacture up to 3 billion tablets and capsules. Our highly experienced, industry-leading team of professionals offers a number of available technologies and solutions that facilitate the commercialization of high-quality products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, please contact Frontida at BD@Frontidabiopharm.com or call +1 (215) 807-1350.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Marc Brookland&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1323583&amp;quot;&amp;gt;Click to Email Marc Brookland&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://frontidabiopharm.com/&amp;quot;&amp;gt;https://frontidabiopharm.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1323583&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=252063" rel="enclosure" title="Logo for Frontida BioPharm, Inc."/>
  </entry>
  <entry>
    <title type="text">When Treating Chronic Prostatitis, by Contrast with Antibiotics, Herbal Medicine Diuretic and Anti-Inflammatory Pill Is More Favored</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2020-12-11T10:44:00-06:00</published>
    <updated>2020-12-11T10:44:00-06:00</updated>
    <author>
      <name>Lee Xiaoping</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=109228&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;Commonly, antibiotics can induce drug resistance, especially in the treatment of chronic diseases. Long-term use of antibiotics is more likely to induce the emergence of drug-resistant microbes. The same is true of chronic prostatitis. While the herbal medicine Diuretic and Anti-inflammatory Pill can avoid this problem well, and it can effectively kill bacteria and eliminate inflammation, which has been favored by many patients with chronic prostatitis.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Los Angeles, CA -- (ReleaseWire) -- 12/11/2020 -- At present, antibiotic makers have struggled with anemic investment and bankruptcies, even after the approval of new drugs, as fears of drug-resistant microbes force hospitals to adopt a more conservative approach toward such treatments, according to the Reuters. Besides, public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the COVID-19 pandemic.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://uk.reuters.com/article/idUKKBN24A1YV&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;https://uk.reuters.com/article/idUKKBN24A1YV&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
It&amp;#039;s clear that the antibiotic market is facing a huge crisis. As a result, several large drug makers including Merck &amp;amp; Co Inc and Pfizer Inc have unveiled a $1 billion fund to bolster struggling antibiotic companies. But this is ultimately a palliative. Antibiotics can induce &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.diureticspill.com/News/2017/0301/862.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.diureticspill.com/News/2017/0301/862.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;drug resistance&amp;lt;/a&amp;gt;, especially in the treatment of chronic diseases, and long-term use of these drugs is more likely to induce the emergence of drug-resistant microbes. No amount of money can change that, so antibiotics will continue to be in an awkward situation when treating chronic diseases.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
It&amp;#039;s well known that many diseases are classified into acute and chronic types, while chronic diseases have more complex causes and longer treatment duration, which are important in the pharmaceutical market. Among them, chronic prostatitis is a very common one in male patients, and it can be divided into &amp;lt;a href=&amp;quot;https://prostatitisradicalcure.com/a/Prostatitis/&amp;quot;&amp;gt;bacterial prostatitis and nonbacterial prostatitis&amp;lt;/a&amp;gt; .&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Antibiotics are mainly used to kill bacteria, so they are not suitable for the treatment of chronic nonbacterial prostatitis. As for the bacteria one, about 80% of inflammation is caused by escherichia coli, and the left 20% involves proteus vulgaris, corynebacterium and so on. Usually, quinolones or cephalosporins can be used for the treatment. But the treatment of chronic inflammation generally lasts a long time. If there is an over-dependence on antibiotics, drug resistance will be inevitable, which will not bring a positive effect on patients.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Why do antibiotics induce drug resistance? Due to genetic diversity, some bacteria in the body are resistant to a certain antibiotic. After the heavy use of this drug, you actually killed other kinds of bacteria, while this kind survives. In the long run, this antibiotic-resistant bacteria can multiply massively, leaving the antibiotic helpless.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Therefore, antibiotics aren&amp;#039;t a good treatment option for chronic prostatitis, whether it is bacterial or nonbacterial. Besides, antibiotics can trigger many side effects on human body, such as dizziness, diarrhea, and so on. As a result, more and more patients with chronic prostatitis are looking for treatments without drug resistance or side effects, and the herbal medicine &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.diureticspill.com/Product/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.diureticspill.com/Product/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;Diuretic and Anti-inflammatory Pill&amp;lt;/a&amp;gt; is a good option, which has been favored by many patients.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Diuretic and Anti-inflammatory Pill is a &amp;lt;a href=&amp;quot;https://prostatitisradicalcure.com/a/Radical_Cure/Chinese_Medicine/2011/0401/379.html&amp;quot;&amp;gt;traditional Chinese medicine&amp;lt;/a&amp;gt; (TCM) product developed by Wuhan Dr.Lee&amp;#039;s TCM Clinic. It&amp;#039;s made of more than 50 Chinese herbs, and each one is carefully selected under strict rules and weight ratio. It&amp;#039;s a reasonable herbal formula summed up by Dr. Lee&amp;#039;s 30 years of clinical experience, which can clear away heat and toxin, kill bacteria, reduce swelling, and promote blood circulation.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The formula contains honeysuckle, houttuynia and other herbs, which can effectively kill all kinds of bacteria and viruses that cause prostatitis. It also contains plantain seed, qumai and bianxu, which can help to improve frequent urination, urgent urination, endless urination and other symptoms, making the urination unobstructed. Additionally, peach kernel, safflower and the like in the formula can effectively eliminate edema, hypertrophy, tumor, etc. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Due to diverse and significant effects, the herbal medicine Diuretic and Anti-inflammatory Pill can be used as a good treatment for chronic prostatitis, and it also plays a therapeutic role in curing &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.diureticspill.com/Medical_Use/Seminal_Vesiculitis/20130819/478.html&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.diureticspill.com/Medical_Use/Seminal_Vesiculitis/20130819/478.html&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;seminal vesiculitis&amp;lt;/a&amp;gt;, orchitis, epididymitis, urinary tract infection and other diseases related to the urogenital system.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
By contrast with antibiotics, TCM is not easy to reduce drug resistance. Generally, one certain antibiotic is used to fight against one disease or bacterium. While TCM stresses the role of &amp;quot;physiological conditioning&amp;quot; to kill bacteria through body immunity. Ingredients of TCM are usually complex, and it can fully terminate bacteria, so it will hardly induce drug resistance. The Diuretic and Anti-inflammatory Pill is a pure Chinese medicine with no drug resistance or side effects, so it&amp;#039;s suitable for patients with chronic prostatitis to take for a long time.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Recently, a patient left a message about his experience in treating chronic prostatitis. Mr Stone, from the U.S, was diagnosed with acute prostatitis in March last year, when he urinated frequently, accompanied by painful sensation. After taking antibiotics for more than 10 days, his condition was relieved slightly but not resolved completely. He didn&amp;#039;t pay much attention at the time, merely taking oral antibiotics to relieve occasional symptoms.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
At the end of last year, Mr Stone was diagnosed with chronic bacterial prostatitis due to his carelessness and bad living habits like drinking too much alcohol and staying up late. He was afraid to take antibiotics again but he couldn&amp;#039;t find a better way. Fortunately, he was suggested to take Diuretic and Anti-inflammatory Pill by a friend. He took it uncertainly for a month, and it turned out that the effect was very obvious, and his pain became relieved with no side effects. After taking the pill for three months, he happily said that he was doing very well, urinating normally and feeling more vigorous than before.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Indeed, there are many patients like Mr Stone suffering from chronic prostatitis, and after keeping on taking the herbal medicine for a long time, they can achieve great therapeutic effects. Moreover, Diuretic and Anti-inflammatory Pill can help improve male urinary and reproductive health, strengthen body resistance, and has a significant effect on prevention of diseases. We hope that Diuretic and Anti-inflammatory Pill can help more patients with urogenital diseases, so that they can get rid of these troubles and live a healthier life.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information about Diuretic and Anti-inflammatory Pill, please visits: &amp;lt;a href=&amp;quot;https://&amp;lt;a href=&amp;quot;http://www.diureticspill.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.diureticspill.com/&amp;lt;/a&amp;gt;&amp;quot;&amp;gt;https://&amp;lt;a href=&amp;quot;http://www.diureticspill.com/&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.diureticspill.com/&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Dr. Lee Xiaoping&amp;lt;br /&amp;gt;
Dr. Lee Xiaoping graduated from Hubei College of Traditional Chinese Medicine, China. She qualified as a herbalist 30 years ago and is a highly experienced medical professional. She specializes in the field of male and female reproductive and urinary system diseases. She has devoted 30 years to her clinic and worked on the formula of Diuretic and Anti-inflammatory Pill for years. The medicine has proven to be effective and cured thousands of people who suffered from chronic prostatitis as well as its complications.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Xiaoping Lee&amp;lt;br /&amp;gt;Herbalist&amp;lt;br /&amp;gt;Wuhan Dr.Lee&amp;#039;s TCM Clinic&amp;lt;br /&amp;gt;Telephone: +86-027-87105085&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1319860&amp;quot;&amp;gt;Click to Email Xiaoping Lee&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://www.drleetcmclinic.com/&amp;quot;&amp;gt;https://www.drleetcmclinic.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1319860&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=109228" rel="enclosure" title="Logo for Lee Xiaoping"/>
  </entry>
  <entry>
    <title type="text">Frontida BioPharm, Inc. has Been Recognized as a Minority Owned Contract Development and Manufacturing Organization</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2020-12-10T09:55:00-06:00</published>
    <updated>2020-12-10T09:55:00-06:00</updated>
    <author>
      <name>Frontida BioPharm, Inc.</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=252063&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Philadelphia, PA -- (ReleaseWire) -- 12/10/2020 -- Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, has been granted full certifiable recognition by The Eastern Minority Supplier Development Council as a Minority-Owned Business Enterprise (certified MBE).&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The Eastern Minority Supplier Development Council (EMSDC) is a 501(c)(3) non-profit organization and nationally recognized affiliate of the National Minority Supplier Development Council (NMSDC). The EMSDC certifies minority-owned, operated and controlled businesses throughout Pennsylvania, Southern New Jersey, and Delaware. The NMSDC is the only organization capable of providing this specific validation and certification throughout the U.S. It advocates business opportunities for certified minority business enterprises and connects them to corporate members who maintain initiatives to support such enterprises.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Song Li, Chairman and founder of Frontida, remarked that, &amp;quot;We are grateful to the NMSDC for the MBE certification and to its eastern region affiliate for facilitating the selection process. From the founding of this organization, when we preserved over 150 jobs in Philadelphia and Chicago areas, to our current 214 employees, Frontida has proudly supported a diverse culture of excellence at all levels of our operations for the benefit of our personnel and our clients. We strive to devote our team&amp;#039;s intellectual and operational capabilities to support pharmaceutical companies in bringing innovative therapies to the market.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Frontida BioPharm, Inc.&amp;lt;br /&amp;gt;
Frontida BioPharm, Inc. is a U.S. based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. Our team is dedicated to helping clients and partners reach the market as quickly and efficiently as possible. Frontida supports pharmaceutical companies in the development, scale-up, and commercial manufacturing of immediate and controlled-release oral solid dose, powder, and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Our 325,000+ sq. ft. manufacturing facilities located in Philadelphia, Pa. and Aurora, Ill. offer a comprehensive suite of solutions for the development and commercialization of prescription, OTC, Highly Potent Active compounds, Phase I through Phase III clinical trial materials, Fixed-dose Combination products, and DEA schedule II&amp;ndash;V products. Frontida is equipped with multiple world-class commercial packaging lines, capable of validated product serialization and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. Frontida has an annual capacity of 3 billion tablets and capsules. Our highly experienced, industry-leading team of professionals offers a number of available technologies and solutions that facilitate the commercialization of high-quality products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, please contact Frontida at BD@Frontidabiopharm.com or call +1 (215) 807-1350&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Marc Brookland&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1319850&amp;quot;&amp;gt;Click to Email Marc Brookland&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://frontidabiopharm.com/&amp;quot;&amp;gt;https://frontidabiopharm.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1319850&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=252063" rel="enclosure" title="Logo for Frontida BioPharm, Inc."/>
  </entry>
  <entry>
    <title type="text">Frontida BioPharm, Inc. Announces Puneet Sapra as New Chief Financial Officer</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2020-12-02T12:35:00-06:00</published>
    <updated>2020-12-02T12:35:00-06:00</updated>
    <author>
      <name>Frontida BioPharm, Inc.</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=252063&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Philadelphia, PA -- (ReleaseWire) -- 12/02/2020 -- Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the appointment of Puneet Sapra as new Chief Financial Officer. Mr. Sapra will be replacing Andrew Wang, who recently accepted the CFO role at Frontage Holdings Corporation, a Contract Research Organization based in the USA and China (HK 1521). &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Mr. Sapra joins Frontida with over 20 years of pharmaceutical and healthcare experience in executive roles at Pfizer Inc., Johnson &amp;amp; Johnson, Halma plc., and J.P. Morgan Chase &amp;amp; Co. His expertise in commercial, operational, and strategic finance comes with commendable notice as CFO of the Year from the Philadelphia Business Journal as well as industry leadership positions such as Chairperson of the Pharmaceuticals Special Interest Group of Financial Executives Networking Group. Mr. Sapra is a graduate of Harvard Business School, Duke University and London School of Economics.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Dr. Song Li, Frontida&amp;#039;s Chairman, remarked that, &amp;quot;Mr. Sapra&amp;#039;s outstanding history in healthcare, strategic planning, capital raising, innovation, and transformative technology reflect highly on both his character as a leader and his professional repute within our industry. We are certain that Puneet will help Frontida advance our corporate growth strategy as we continue to expand and implement new technologies and products in our development and manufacturing operations.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
In response, Mr. Sapra commented, &amp;quot;I&amp;#039;m very excited to join Dr. Li and the entire team at Frontida. I share Frontida&amp;#039;s passion for advancing innovation in life sciences and I hope to use my skills to help accelerate Frontida&amp;#039;s exciting growth trajectory.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Frontida BioPharm, Inc.&amp;lt;br /&amp;gt;
Frontida BioPharm, Inc. is a U.S. based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. Our team is dedicated to helping clients and partners reach the market as quickly and efficiently as possible. Frontida supports pharmaceutical companies in the development, scale-up, and commercial manufacturing of immediate and controlled-release oral solid dose, powder, and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Our 325,000+ sq. ft. manufacturing facilities located in Philadelphia, Pa. and Aurora, Ill. offer a comprehensive suite of solutions for the development and commercialization of prescription, OTC, Highly Potent Active compounds, Phase I through Phase III clinical trial materials, Fixed-dose Combination products, and DEA schedule II&amp;ndash;V products. Frontida is equipped with multiple world-class commercial packaging lines, capable of validated product serialization and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. Frontida has an annual capacity of 3 billion tablets and capsules. Our highly experienced, industry-leading team of professionals offers a number of available technologies and solutions that facilitate the commercialization of high-quality products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, please contact Frontida at BD@Frontidabiopharm.com or call +1 (215) 807-1350&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Marc Brookland&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1318707&amp;quot;&amp;gt;Click to Email Marc Brookland&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://frontidabiopharm.com/&amp;quot;&amp;gt;https://frontidabiopharm.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1318707&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=252063" rel="enclosure" title="Logo for Frontida BioPharm, Inc."/>
  </entry>
  <entry>
    <title type="text">Pacemaker Procedures Globally Will Reach 2 Million by 2025</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2020-11-30T08:00:00-06:00</published>
    <updated>2020-11-30T08:00:00-06:00</updated>
    <author>
      <name>iData Research</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=274411&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p class=&amp;quot;subheadline&amp;quot;&amp;gt;Recent study projects millions of patients having pacemaker surgery by 2025 as new technologies and improvements lead to a higher number of devices implanted.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Vancouver, BC -- (ReleaseWire) -- 11/30/2020 -- A recent study projects that nearly 2 million patients will undergo surgery for pacemaker insertion and replacement by 2025. According to &amp;lt;a href=&amp;quot;https://bit.ly/3jiwz9H&amp;quot;&amp;gt;iData Research&amp;lt;/a&amp;gt;, a global consulting and market research firm, the capabilities and battery lifespan of pacemakers have increased in the last decade, and wireless technology is expected to make it easier for doctors to maintain and adjust pacemaker function. As a result, new technologies will keep prices high and lead to a higher number of devices implanted.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
iData&amp;#039;s Global Pacemaker Market Report forecasts a total market size of $2.6 billion in 2025. The report also highlights that most pacemaker surgeries will be carried out in North American hospitals. The trends in procedure numbers also show consistent growth in Asia and Africa. However, across the U.S., a tight competitive landscape could slow down growth rates for the market when it comes to pacemaker sales. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;quot;We use a proprietary method to combine statistical data and industry experts&amp;#039; opinions to estimate current and future market values and procedure numbers. Based on that, we can accurately estimate the market for lifesaving medical devices like pacemakers.&amp;quot; said Dr. Kamran Zamanian, CEO of iData Research. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Among many competitors in the global pacemaker market, Medtronic, Abbott and Boston Scientific are the leaders by varying market shares. Innovation is a vital factor in the competitive landscape. Medtronic pioneered the development of pacemakers and has long been the leading pacemaker manufacturer. Medtronic&amp;#039;s remote monitoring CareLink&amp;reg; network is compatible with its pacemakers and allows patients to check their pacemaker&amp;#039;s status from home, thereby reducing the number of doctor visits.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information on the global market for pacemakers, follow the link below to get a Free Research Summary of the Global Market Report for Pacemaker Devices:&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://idataresearch.com/product/pacemaker-market/?utm_source=ReleaseWire&amp;amp;utm_medium=PressRelease&amp;amp;utm_campaign=GLPM&amp;quot;&amp;gt;Research Summary of the Global Market Report for Pacemaker Devices&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
The Global Market Report for Pacemaker Devices contains a full overview of the disease, a detailed assessment of the available pacemakers in the market, a global overview of trends, market drivers/limiters and competitive outlook, along with forecasts on procedure numbers, market values and growth projections by each of the analyzed 65 countries and respective regions.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For Further Information&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
More insights like this can be found in the latest reports and publications by iData. Please email us at info@idataresearch.net &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About iData&amp;lt;br /&amp;gt;
iData Research is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, and pharmaceutical industries.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For 15 years, iData Research has been a strong advocate for data-driven decision-making within the global medical device, dental, and pharmaceutical industries. By providing custom research and consulting solutions, iData empowers its clients to trust the source of data and make important strategic decisions with confidence.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
&amp;lt;a href=&amp;quot;https://idataresearch.com/&amp;quot;&amp;gt;&amp;lt;a href=&amp;quot;http://www.idataresearch.com&amp;quot; target=&amp;quot;_blank&amp;quot;&amp;gt;http://www.idataresearch.com&amp;lt;/a&amp;gt;&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Antonio Collet&amp;lt;br /&amp;gt;Marketing Manager&amp;lt;br /&amp;gt;Telephone: 1-604-266-6933&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1317896&amp;quot;&amp;gt;Click to Email Antonio Collet&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://idataresearch.com/&amp;quot;&amp;gt;https://idataresearch.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1317896&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=274411" rel="enclosure" title="Logo for iData Research"/>
  </entry>
  <entry>
    <title type="text">Frontida BioPharm, Inc. Announces Praful Agrawala, Ph.D., as Executive Vice President, Technology</title>
    <link href="http://www.releasewire.com/press-releases/release-3.htm" type="text/html"/>
    <id>http://www.releasewire.com/press-releases/release-3.htm</id>
    <published>2020-11-19T09:51:00-06:00</published>
    <updated>2020-11-19T09:51:00-06:00</updated>
    <author>
      <name>Frontida BioPharm, Inc.</name>
    </author>
    <media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="http://media.releasewire.com/photos/show/?id=252063&amp;amp;size=small"/>
    <content type="html"><![CDATA[&amp;lt;div class=&amp;quot;newsbody&amp;quot;&amp;gt;&amp;lt;p&amp;gt;Philadelphia, PA -- (ReleaseWire) -- 11/19/2020 -- Frontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the appointment of Praful Agrawala, Ph.D., as Executive Vice President, Technology. Dr. Agrawala adds years of pharmaceutical product development leadership experience to Frontida after serving in executive roles at Amneal Pharmaceuticals, Sanofi-Aventis, and Schering-Plough Research Institute. &amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Dr. Agrawala&amp;#039;s core competencies include product development, discovery research interfacing, preclinical evaluation, clinical and CMC development of new chemical entities, inhalation product development, drug-device combinations development, manufacturing process development and commercialization, contract development &amp;amp; manufacturing, licensing, alliance management and platform technology evaluations. Dr. Agrawala joins Frontida with a noteworthy scientific background including experience in multiple dosage form development of long-acting injectables, sterile solutions, MDI and DPI inhalation products and devices, modified release tablets, rapidly disintegrating tablets, oral and nasal suspensions, oral solutions, semi-solids and transdermal products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Anthony Qu, Frontida&amp;#039;s COO, remarked that, &amp;quot;Dr. Agrawala&amp;#039;s proven track record in developing complex formulations of long-acting and immediate release injectables, inhalation and oral dosage forms showcases his extensive background in pharmaceutics, quality and regulatory aspects of branded and generic product development. Our team is excited to have Dr. Agrawala join us during this intensive growth phase at Frontida.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
In response, Dr. Agrawala commented, &amp;quot;I am delighted to join Frontida Biopharm at this time of tremendous growth for the company. I look forward to working with the teams at Frontida to advance the company&amp;#039;s broad portfolio of drug delivery technologies, product development and manufacturing services for pharmaceutical companies.&amp;quot;&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
About Frontida BioPharm, Inc.&amp;lt;br /&amp;gt;
Frontida BioPharm, Inc. is a U.S. based, minority-owned CDMO providing drug delivery technologies, product development, and manufacturing services for pharmaceutical and consumer health companies. Our team is dedicated to helping clients and partners reach the market as quickly and efficiently as possible. Frontida supports pharmaceutical companies in the development, scale-up, and commercial manufacturing of immediate and controlled-release oral solid dose, powder, and liquid products; ensuring robust product performance and on-time supply of clinical trial materials and commercial products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
Our 325,000+ sq. ft. manufacturing facilities located in Philadelphia, Pa. and Aurora, Ill. offer a comprehensive suite of solutions for the development and commercialization of prescription, OTC, Highly Potent Active compounds, Phase I through Phase III clinical trial materials, Fixed-dose Combination products, and DEA schedule II&amp;ndash;V products. Frontida is equipped with multiple world-class commercial packaging lines, capable of validated product serialization and providing packaging services for both commercial products and clinical trial material supplies in bottles and blisters. Frontida has an annual capacity of 3 billion tablets and capsules. Our highly experienced, industry-leading team of professionals offers a number of available technologies and solutions that facilitate the commercialization of high-quality products.&amp;lt;br /&amp;gt;
&amp;lt;br /&amp;gt;
For more information, please contact Frontida at BD@Frontidabiopharm.com or call +1 (215) 807-1350&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;For more information on this press release visit: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/release-3.htm&amp;quot;&amp;gt;http://www.releasewire.com/press-releases/release-3.htm&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;h2&amp;gt;Media Relations Contact&amp;lt;/h2&amp;gt;&amp;lt;p&amp;gt;Marc Brookland&amp;lt;br /&amp;gt;Email: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;http://www.releasewire.com/press-releases/contact/1316993&amp;quot;&amp;gt;Click to Email Marc Brookland&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;Web: &amp;lt;a rel=&amp;quot;nofollow&amp;quot; href=&amp;quot;https://frontidabiopharm.com/&amp;quot;&amp;gt;https://frontidabiopharm.com/&amp;lt;/a&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;/div&amp;gt;&amp;lt;div&amp;gt;&amp;lt;p&amp;gt;&amp;lt;img src=&amp;quot;https://cts.releasewire.com/v/?sid=1316993&amp;amp;amp;s=f&amp;amp;amp;v=f&amp;quot; width=&amp;quot;1&amp;quot; height=&amp;quot;1&amp;quot; alt=&amp;quot;&amp;quot;&amp;gt;&amp;lt;span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;/div&amp;gt;]]></content>
    <link href="http://media.releasewire.com/photos/show/?id=252063" rel="enclosure" title="Logo for Frontida BioPharm, Inc."/>
  </entry>
</feed>
